Open Orphan – Result of General Meeting June 11, 2020 – Posted in: Open Orphan (ORPH) – Tags: , , ,

Thursday 11th June, 2020

Open Orphan plc

(“Open Orphan”, or the “Company”)

Result of General Meeting

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models, is pleased to announce that at the Company’s General Meeting held earlier today in relation to the Fundraising, all of the Resolutions put to the meeting were duly passed.

The Conditional Fundraise remains conditional on Admission of the relevant Conditional Fundraising Shares to AIM and Euronext Growth, which is expected to take place at 8.00 a.m. on Friday 12 June 2020.

Total Voting Rights

Following the Admission of the Conditional Fundraising Shares, the total number of Ordinary Shares in the Company in issue will be 663,860,098. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA’s Disclosure and Transparency Rules.

Unless otherwise defined, capitalised terms used in this announcement are as defined in the Circular.

For further information please contact

Open Orphan plc

+353 (0)1 644 0007

Cathal Friel, Executive Chairman

Arden Partners plc (Nominated Adviser and Joint Broker)

+44 (0)20 7614 5900

John Llewellyn-Lloyd / Benjamin Cryer / Dan Gee-Summons

finnCap plc (Joint Broker)

+44 (0) 20 7220 0500

Geoff Nash / James Thompson / Charlie Beeson

Davy (Euronext Growth Adviser and Joint Broker)

+353 (0)1 679 6363

Anthony Farrell

Camarco (Financial PR)

+44 (0)20 3757 4980

Tom Huddart / Hugo Liddy